Market Place
Sourcing Support
ObsEva Announces Delisting from SIX Swiss Exchange & Exemption
03 Apr 2024 //
GLOBENEWSWIRE
ObsEva Announces Update on Board of Directors
19 Mar 2024 //
GLOBENEWSWIRE
ObsEva winds down and lays off staff as money, options run out
28 Feb 2024 //
FIERCE BIOTECH
ObsEva Announces Wind-Down of Operations
27 Feb 2024 //
GLOBENEWSWIRE
Geneva Court Grants Temporary Moratorium to ObsEva
31 Jan 2024 //
GLOBENEWSWIRE
ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals
30 Nov 2023 //
GLOBENEWSWIRE
ObsEva Files half Year 2023 Financial Statements
27 Sep 2023 //
GLOBENEWSWIRE
ObsEva gets China rights to pregnancy drug over missed deadline
13 Jul 2023 //
FIERCE BIOTECH
ObsEva Recovers Full Worldwide Rights on Nolasiban
13 Jul 2023 //
GLOBENEWSWIRE
ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2023
30 Jun 2023 //
GLOBENEWSWIRE
Annual General Meeting 2023
08 Jun 2023 //
GLOBENEWSWIRE
ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer
02 May 2023 //
GLOBENEWSWIRE
ObsEva Files Year End 2022 Financial Statements
31 Mar 2023 //
GLOBENEWSWIRE
ObsEva Announces Progress Towards Plans to Consolidate Operations in Switzerland
15 Mar 2023 //
PRESS RELEASE
ObsEva Announces Update Towards its Strategic Reorganization
13 Mar 2023 //
GLOBENEWSWIRE
ObsEva Announces Reorganization to Consolidate Operations in Switzerland
24 Feb 2023 //
GLOBENEWSWIRE
ObsEva demolishes US C-suite as Nasdaq delisting looms
24 Feb 2023 //
FIERCE BIOTECH
ObsEva Announces Dismissal of Moratorium Proceedings
19 Dec 2022 //
GLOBENEWSWIRE
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule
14 Dec 2022 //
GLOBENEWSWIRE
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule
14 Dec 2022 //
GLOBENEWSWIRE
ObsEva Announces 3Q 2022 Financial Results and Provides a Business Update
01 Dec 2022 //
GLOBENEWSWIRE
ObsEva Announces Sale of Ebopiprant Agreement to XOMA for up to $113 Million
22 Nov 2022 //
GLOBENEWSWIRE
ObSeva sells off one of 2 remaining assets to stay afloat
22 Nov 2022 //
FIERCEBIOTECH
ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 M
21 Nov 2022 //
GLOBENEWSWIRE
ObsEva Announces Progress on Cost Reduction Initiatives
26 Oct 2022 //
GLOBENEWSWIRE
ObsEva Announces IND Approval for Yuyuan Bioscience’s Pha1 Trial of Nolasiban
13 Oct 2022 //
GLOBENEWSWIRE
ObsEva`s restructuring claims 70% of its staffers — reaching into the C-suite
14 Sep 2022 //
ENPTS
ObsEva Announces Progress on Restructuring Initiatives
12 Sep 2022 //
GLOBENEWSWIRE
ObsEva Receives Nasdaq Non-Compliance Notice
22 Aug 2022 //
GLOBENEWSWIRE
ObsEva Files Second Quarter 2022 Financial Statements
17 Aug 2022 //
GLOBENEWSWIRE
ObsEva Scraps Plans for Uterine Fibroid Candidate
02 Aug 2022 //
FDANEWS
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing
01 Aug 2022 //
GLOBENEWSWIRE
ObsEva Announces Management Change
29 Jul 2022 //
GLOBENEWSWIRE
Women`s health firm launches major reorg after ominous FDA note
28 Jul 2022 //
FIERCEPHARMA
ObsEva Announces Corporate Updates
26 Jul 2022 //
GLOBENEWSWIRE
ObsEva Announces UK MHRA Marketing Authorization for Yselty in Uterine Fibroids
28 Jun 2022 //
GLOBENEWSWIRE
ObsEva Announces EC Marketing Authorization for Yselty inUterine Fibroids
17 Jun 2022 //
GLOBENEWSWIRE
ObsEva Announces Corporate Updates
27 May 2022 //
GLOBENEWSWIRE
ObsEva Presents Data on Oral GnRH Antagonist Linzagolix
25 May 2022 //
GLOBENEWSWIRE
ObsEva SA Announces that Shareholders Approved all Board Proposals
19 May 2022 //
GLOBENEWSWIRE
ObsEva Appoints Annette Clancy as Chair of the Board of Directors
19 May 2022 //
GLOBENEWSWIRE
ObsEva Announces First Quarter 2022 Financial Results
17 May 2022 //
GLOBENEWSWIRE
ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference
16 May 2022 //
GLOBENEWSWIRE
ObsEva to Discuss First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
ObsEva Presents Data on Oral GnRH Antagonist Linzagolix for Uterine Fibroids
09 May 2022 //
GLOBENEWSWIRE
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
02 May 2022 //
GLOBENEWSWIRE
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
02 May 2022 //
GLOBENEWSWIRE
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix
25 Apr 2022 //
GLOBENEWSWIRE
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix
25 Apr 2022 //
GLOBENEWSWIRE
ObsEva Annual General Meeting 2022
06 Apr 2022 //
GLOBENEWSWIRE
ObsEva Annual Report 2021
31 Mar 2022 //
GLOBENEWSWIRE
ObsEva Annual Report 2021
31 Mar 2022 //
GLOBENEWSWIRE
ObsEva has Efficacy for Linzagolix 200 mg with ABT, Linzagolix 75 mg without ABT
22 Mar 2022 //
GLOBENEWSWIRE
ObsEva says Year End 2021 Financial Results
10 Mar 2022 //
GLOBENEWSWIRE
Theramex, ObsEva Sign Licensing Agreement for Linzagolix in Uterine Fibroids
10 Feb 2022 //
BUSINESSWIRE
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix
04 Feb 2022 //
GLOBENEWSWIRE
ObsEva Announces Corporate Updates
28 Jan 2022 //
GLOBENEWSWIRE
ObsEva Announces Positive Topline Results for Linzagolix 200 mg in Phase 3
06 Jan 2022 //
GLOBENEWSWIRE
ObsEva Added to the NASDAQ Biotechnology Index
20 Dec 2021 //
GLOBENEWSWIRE
ObsEva Added to the NASDAQ Biotechnology Index
20 Dec 2021 //
GLOBENEWSWIRE
